Zobrazeno 1 - 10
of 40
pro vyhledávání: '"James B. Streisand"'
Autor:
Janet E. Pope, James B. Streisand, Christopher P. Denton, Maureen D. Mayes, Daniel E. Furst, Peter A. Merkel, Richard P. Polisson, Nancy P. Silliman, James R. Seibold, P. J. Clements
Publikováno v:
Arthritis & Rheumatism. 64:3420-3429
To examine the range and responsiveness to change of clinical outcome measures and study predictors of clinical response in patients with diffuse cutaneous systemic sclerosis (dcSSc) in the context of clinical trials.Data were combined from 629 patie
Publikováno v:
Clinical Pharmacokinetics. 41:661-680
Oral mucosal drug delivery is an alternative method of systemic drug delivery that offers several advantages over both injectable and enteral methods. Because the oral mucosa is highly vascularised, drugs that are absorbed through the oral mucosa dir
Antithrombin (AT) is a 65 kDa glycoprotein belonging to a group of inhibitory factors known as serpins (serine protease inhibitors). It plays a critical role in the inhibition of coagulation and inflammation processes within the environment of the va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f760004d2e6f54bb65f6a58b63a01bad
http://hdl.handle.net/10281/157354
http://hdl.handle.net/10281/157354
Autor:
Jur Kievit, Talmage D. Egan, James B. Streisand, Michael A. Ashburn, Nathan L. Pace, Amarnath Sharma
Publikováno v:
Anesthesiology. 92:665-673
Background Oral transmucosal fentanyl citrate (OTFC) is a solid form of fentanyl that delivers the drug through the oral mucosa. The clinical utility of multiple doses of OTFC in the treatment of "breakthrough" cancer pain is under evaluation. The ai
Autor:
Perry G. Fine, James B. Streisand
Publikováno v:
Journal of Palliative Medicine. 1:55-63
The physiochemical characteristics of the potent synthetic opioid agonist fentanyl make it ideal for noninvasive transmucosal delivery. Studies of oral transmucosal fentanyl citrate (OTFC), a candied matrix formulation administered orally as a palata
Autor:
James B. Streisand, George Graf, Joel Yarmush, Barbara Kirkhart, Peter S. Sebel, Laurie Maysick, Colleen O Leary, Melvin Pitts, W. David Watkins, Robert D Angelo, Dragomir Vujic, Rafael Miguel
Publikováno v:
Anesthesiology. 87:235-243
Background The transition from remifentanil intraoperative anesthesia to postoperative analgesia must be planned carefully due to the short duration of action (3-10 min) of remifentanil hydrochloride, a potent, esterase-metabolized mu-opioid agonist.
Autor:
Randal Batenhorst, Charles W. Hogue, Colleen E. O'leary, George V. Kirvassilis, Sally McNeal, Deryck Duncalf, Melvin Pitts, James B. Streisand, Brenda D. Jamerson, Rafael Miguel, T. Andrew Bowdle
Publikováno v:
Anesthesia & Analgesia. 83:279-285
Remifentanil is a mu-opioid receptor agonist with a context sensitive half-time of 3 min and an elimination half-life < or = 10 min. This study sought to evaluate the efficacy of remifentanil and propofol total intravenous anesthesia (TIVA) in 161 pa
Publikováno v:
American Journal of Obstetrics and Gynecology. 214:S404
Autor:
Michael A. Ashburn, James B. Streisand, Brian Hague, Stephen D. Tarver, John R. Varvel, Donald R. Stanski, Leon Le Maire, Theodore H. Stanley
Publikováno v:
Anesthesiology. 75:223-229
Oral transmucosal fentanyl citrate (OTFC) is a novel, noninvasive dosage form of fentanyl used to provide children and adults with sedation, anxiolysis, and analgesia. In order to determine the bioavailability and absorption of fentanyl from OTFC, 12
Autor:
Ariane L. Herrick, James B. Streisand, Douglas J. Veale, Vivien Hsu, Christopher P. Denton, Joseph H. Korn, Dinesh Khanna, Frank J. A. van den Hoogen, Nancy P. Silliman, Richard P. Polisson, Paul Emery, Carol M. Black, James R. Seibold, John Coppock, Daniel E. Furst, Maureen D. Mayes, Anita Åkesson, Peter A. Merkel
Objective. To determine the validity, reliability, and feasibility of durometer measurements of skin hardness as an outcome measure in clinical trials of scleroderma. Methods. Skin hardness was measured during a multicenter treatment trial for sclero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97e32397d56a101545aa61601b5415ce
https://europepmc.org/articles/PMC3887555/
https://europepmc.org/articles/PMC3887555/